Investigator-initiated, prospective, non-randomised trial of vernakalant for the treatment of new-onset atrial fibrillation in patients undergoing cardiac interventions.

Trial Profile

Investigator-initiated, prospective, non-randomised trial of vernakalant for the treatment of new-onset atrial fibrillation in patients undergoing cardiac interventions.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2014

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Feb 2014 New trial record
    • 13 Feb 2014 Results have been presented at the 43rd Annual Meeting of the Germany Society for Thoracic and Cardiovascular Surgery according to a Cardiome Pharma media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top